Results 241 to 250 of about 70,416 (256)

Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma—data from the Czech registry

Annals of Oncology, 2012
Tomas Buchler, B Melichar, R Vyzula
exaly  

Sorafenib

Reactions Weekly, 2022
openaire   +1 more source

Sorafenib

Reactions Weekly
openaire   +2 more sources

A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study

Annals of Oncology, 2012
Ymera Pignochino, Giovanni Grignani, Massimo Aglietta   +2 more
exaly  

Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors

Annals of Oncology, 2006
H Richly, R A Hilger, E Brendel
exaly  

Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib

Annals of Oncology, 2008
Mario E Lacouture, P Gerami
exaly  

Sorafenib

Reactions Weekly, 2023
openaire   +1 more source

BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer

Annals of Oncology, 2012
Dominique GENRE, Patrice Viens, R Lamy
exaly  

Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial†

Annals of Oncology, 2013
Elena Verzoni, Giuseppe Procopio, Rosalba Miceli   +2 more
exaly  

Nanoparticles for controlled release of Sorafenib and Sorafenib derivatives

2018
PITARRESI GIOVANNA, CERVELLO MELCHIORRE, AZZOLINA ANTONINA, PULEIO ROBERTO, LORIA GUIDO RUGGERO, PULEO STEFANO, GIAMMONA GAETANO   +6 more
openaire   +3 more sources